Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc (N:BHC)

Business Focus: Pharmaceuticals

INK Edge Outlook

Mostly sunny as of January 01, 2022
For the latest outlook, get the company report

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEC Form 4 filings for BHC*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 18, 2022 06:48 ET
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
LAVAL, QB, Jan. 18, 2022 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the initial public offering (IPO) of Bausch + Lomb Corporation ("Bausch +
Read full article
Jan 18, 2022 06:48 ET
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
LAVAL, QB, Jan. 18, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the initial public offering (IPO) of Bausch + Lomb Corporation ("B
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.62
--
--
Price to Sales - TTM
1.13
5.72
6.38
Price to Book - most recent quarter
--
2.12
2.60
Price to Cash Flow per share - TTM
20.97
13.14
14.93
Price to Free Cash Flow per share - TTM
6.32
23.49
27.41
See all valuations

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. Its segments include Bausch + Lomb, Salix, Ortho Dermatologics, International Rx and Diversified Products. The Bausch + Lomb segment consists of sales in the United States of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmology Rx products. The Salix segment consists of sales in the United States of gastroenterology (GI) products. The Ortho Dermatologics segment consists of sales in the United States of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices.

See business summary

 

Twitter

Search (past week) for $BHC